Patents by Inventor Hwan Geun Choi

Hwan Geun Choi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10913744
    Abstract: Compounds having the formula I, II, or III: are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: February 9, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, John Hatcher, Hwan Geun Choi
  • Patent number: 10875844
    Abstract: Provided herein are small molecule inhibitors of maternal embryonic leucine zipper kinase (MELK) having the structure of formula (I), wherein X and R1-R3 are defined in the specification. The compounds are useful for treating cancer and other conditions or diseases associated with aberrant MELK expression. Also provided herein are pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The invention also provides methods of treating cancers associated with over-expression of MELK.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: December 29, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Tinghu Zhang, Hai-Tsang Huang, Yubao Wang, Jean Zhao, Hwan Geun Choi
  • Patent number: 10870636
    Abstract: The application relates to a compound having Formula (I): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: December 22, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Pasi Janne, Hwan Geun Choi, Jaebong Jang
  • Patent number: 10870647
    Abstract: The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: December 22, 2020
    Assignee: DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION
    Inventors: Hwan Geun Choi, Jung Beom Son, Shinae Kim, Seungyeon Lee, Eunhwa Ko, Joongheui Cho, Seock Yong Kang, So Young Kim, Jin-Hee Park, Yi Kyung Ko, Hee Yoon Ryu, Nam Doo Kim, Hyunkyoung Kim, Younho Lee, Sun-Hwa Lee, Dayea Kim, Sun Joo Lee, Seongho Hong, Sang Hyun Min, Sungwoo Lee, Dong Kyu Choi, Jae Hyun Bae, Eunmi Hong, Tae-Ho Jang, Jaeyoung Song, Sangbum Kim, Suk Kyoon Yoon
  • Patent number: 10844077
    Abstract: The present disclosure provides thiazolyl-containing compounds of Formula (I), (II), or (III). The compounds described herein may be able to inhibit protein kinases (e.g. Src family kinases (e.g. hemopoietic cell kinase (HCK)), Bruton's tyrosine kinase (BTK)) and may be useful in treating and/or preventing proliferative diseases (e.g. myelodysplasia, leukemia, lymphoma, (e.g. Waldenström's macroglobulinemia)) and in inducing apoptosis in a cell (e.g. malignant blood cell). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: November 24, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Sara Jean Buhrlage, Steven P. Treon, Hwan Geun Choi, Yuan Xiong, Guang Yang
  • Patent number: 10836722
    Abstract: The disclosure relates to a compound having Formula (I?): and in particular, Compound I-126: which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: November 17, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Michael Eck, Pasi Janne, Hwan Geun Choi, Jaebong Jang, Kwok-Kin Wong
  • Publication number: 20200338087
    Abstract: The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inhibitors of Formula (II), and urea and carbamate SIK inhibitors of Formula (III-A) (e.g., urea and carbamate STK inhibitors of Formula (III)).
    Type: Application
    Filed: April 19, 2019
    Publication date: October 29, 2020
    Applicants: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc., President and Fellows of Harvard College, The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Alykhan Shamji, Thomas Sundberg, Nathanael S. Gray, Ramnik Xavier, Stuart L. Schreiber, Hwan Geun Choi, Yanke Liang
  • Publication number: 20200317675
    Abstract: The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
    Type: Application
    Filed: July 5, 2017
    Publication date: October 8, 2020
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nathanael S. GRAY, Yanke LIANG, Hwan Geun CHOI, Thomas SUNDBERG, Alykhan SHAMJI, Ramnik XAVIER, David E. FISHER, Nisma MUJAHID
  • Publication number: 20200297721
    Abstract: The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
    Type: Application
    Filed: June 4, 2020
    Publication date: September 24, 2020
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Hwan Geun Choi, Xianming Deng, Jianming Zhang
  • Publication number: 20200253981
    Abstract: The present disclosure provides methods of increasing skin pigmentation in a subject in need thereof using salt-inducible kinase (SIK) inhibitors, such as macrocyclic compounds of Formula (I), bicyclic urea compounds of Formula (II), (III), and (IV), and compounds of Formula (V), (VI), (VI-A), or (VII). Also provided are pharmaceutical compositions, methods, and uses that include or involve a compound described herein.
    Type: Application
    Filed: February 28, 2018
    Publication date: August 13, 2020
    Applicants: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: David E. Fisher, Nisma Mujahid, Ryo Murakami, Nathanael S. Gray, Yanke Liang, Hwan Geun Choi
  • Publication number: 20200239474
    Abstract: The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.
    Type: Application
    Filed: February 22, 2018
    Publication date: July 30, 2020
    Applicants: DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION, NATIONAL CANCER CENTER, SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Hwan Geun CHOI, Jong Bae PARK, Eunhwa KO, Jung Beom SON, Joong-heui CHO, Yi Kyung KO, Jin-Hee PARK, So Young KIM, Seock Yong KANG, Seungyeon LEE, Nam Doo KIM, Yunho LEE, Sun-Hwa LEE, Dayea KIM, Sun Joo LEE, Jae Hyun BAE, Eunmi HONG, Tae-ho JANG, Sang Bum KIM, Seung Hoon LEE, Do-Hyun NAM
  • Patent number: 10723753
    Abstract: Described herein are compounds of Formulae (I)-(II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 28, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Sang Min Lim, Hwan Geun Choi, Kenneth Dale Westover, Matthew Meyerson
  • Publication number: 20200223798
    Abstract: The application relates to a compound of Formula (I): which modulates the activity of ALK or SRPK, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which ALK or SRPK plays a role.
    Type: Application
    Filed: October 30, 2019
    Publication date: July 16, 2020
    Inventors: John HATCHER, Nathanael S. GRAY, Hwan Geun CHOI, Pasi JANNE, Tinghu ZHANG
  • Publication number: 20200207756
    Abstract: The present invention relates to a pyrrolopyridine derivative compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases. A compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has excellent inhibitory activity against various protein kinases including DYRK1A, and therefore, the pharmaceutical composition containing the same as an active ingredient can be favorably used in the treatment or prevention of protein kinase-related diseases. Particularly, the pharmaceutical composition can be effectively used in the prevention, treatment, or alleviation of Alzheimer's disease, dementia, or Alzheimer's dementia.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 2, 2020
    Inventors: Hwan Geun CHOI, Eunhwa KO, Joong-heui CHO, Jung Beom SON, Yi Kyung KO, Jin-Hee PARK, So Young KIM, Seock Yong KANG, Seungyeon LEE, Hee Yoon RYU, Nam Doo KIM, Sang Bum KIM, Sun-Hwa LEE, Dayea KIM, Sun Joo LEE, Sungchan CHO, Kyu-Sun LEE, Kweon YU, Miri CHOI, Ja Wook KOO, Hyang-Sook HOE
  • Publication number: 20200179387
    Abstract: The present disclosure provides methods of treating and/or preventing osteoporosis using salt-inducible kinase (SIK) inhibitors. Also provided are methods of using SIK inhibitors for increasing the function of osteocytes, increasing the number of osteoblasts, increasing the activity of osteoblasts, inhibiting the resorption of a bone, decreasing the number of osteoclasts, inhibiting the activity of osteoclasts, increasing the mass of a bone, down-regulating the expression of the gene SOST, and/or inhibiting the activity of sclerostin. The SIK inhibitors may be combined with Src inhibitors or CSF I R inhibitors. Exemplary SIK inhibitors include the compounds of the formula: (I), (II), (III), (IV), (V) or (VI).
    Type: Application
    Filed: September 16, 2017
    Publication date: June 11, 2020
    Applicants: The General Hospital Corporation, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Marc Wein, Henry Kronenberg, Thomas Sundberg, Ramnik Xavier, Nathanael S. Gray, Yanke Liang, Hwan Geun Choi, Alykhan Shamji
  • Publication number: 20200165267
    Abstract: The present disclosure provides thiazolyl-containing compounds of Formula (I), (II), or (III). The compounds described herein may be able to inhibit protein kinases (e.g. Src family kinases (e.g. hemopoietic cell kinase (HCK)), Bruton's tyrosine kinase (BTK)) and may be useful in treating and/or preventing proliferative diseases (e.g. myelodysplasia, leukemia, lymphoma, (e.g. Waldenström's macroglobulinemia)) and in inducing apoptosis in a cell (e.g. malignant blood cell). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Application
    Filed: November 1, 2019
    Publication date: May 28, 2020
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Sara Jean Buhrlage, Steven P. Treon, Hwan Geun Choi, Yuan Xiong, Guang Yang
  • Publication number: 20200159656
    Abstract: A storage device includes a non-volatile memory including a plurality of memory blocks. The storage device performs an alignment operation in response to receipt of an align command. The alignment operation converts a received logical address of a logical segment into a physical address and allocates the physical address to a physical block address corresponding to a free block. The storage device is further configured to performs a garbage collection in units of the physical block address that indicates one memory block.
    Type: Application
    Filed: August 16, 2019
    Publication date: May 21, 2020
    Inventors: Byoung-Geun Kim, In-Hwan Doh, Joo-Young Hwang, Seung-Uk Shin, Min-Seok Ko, Jae-Yoon Choi
  • Patent number: 10544138
    Abstract: Provided herein are tricyclic small molecule inhibitors of maternal embryonic leucine zipper kinase (MELK). The compounds are useful for treating cancer and other conditions or diseases associated with aberrant MELK expression. Also provided herein are pharmaceutical compositions comprising a tricyclic compound of the invention and a pharmaceutically acceptable carrier. The invention also provides methods of treating cancers associated with over-expression of MELK.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: January 28, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Tinghu Zhang, Hai-Tsang Huang, Yubao Wang, Jean Zhao, Hwan Geun Choi
  • Publication number: 20200002279
    Abstract: The disclosure relates to a compound having Formula (I?): and in particular, Compound I-126: which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: June 13, 2019
    Publication date: January 2, 2020
    Inventors: Nathanael S. GRAY, Michael ECK, Pasi JANNE, Hwan Geun CHOI, Jaebong JANG, Kwok-Kin WONG
  • Patent number: 10508082
    Abstract: The application relates to a compound of Formula (I): which modulates the activity of ALK or SRPK, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which ALK or SRPK plays a role.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: December 17, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: John Hatcher, Nathanael S. Gray, Hwan Geun Choi, Pasi Janne, Tinghu Zhang